Milestone Pharmaceuticals (MIST) to Release Quarterly Earnings on Thursday

Key Points

• Milestone Pharmaceuticals is set to release its Q2 2025 earnings report on August 14th, with analysts predicting a loss of ($0.18) per share.
• The company's previous earnings report showed a larger loss of ($0.31) per share, missing estimates by ($0.12).
• HC Wainwright upgraded Milestone Pharmaceuticals to a "buy" rating with a price target of $5.00, while the average target price among analysts is $7.00.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.12). On average, analysts expect Milestone Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Milestone Pharmaceuticals Stock Performance

NASDAQ MIST traded down $0.01 during trading hours on Friday, hitting $1.50. The company had a trading volume of 460,202 shares, compared to its average volume of 2,678,198. The company has a debt-to-equity ratio of 4.06, a quick ratio of 4.67 and a current ratio of 4.67. Milestone Pharmaceuticals has a 1-year low of $0.63 and a 1-year high of $2.75. The company has a market cap of $80.19 million, a PE ratio of -1.92 and a beta of 0.52. The business has a 50 day moving average of $1.72 and a 200-day moving average of $1.61.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A hedge fund recently raised its stake in Milestone Pharmaceuticals stock. Creative Planning lifted its holdings in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) by 74.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 23,410 shares of the company's stock after buying an additional 10,000 shares during the period. Creative Planning's holdings in Milestone Pharmaceuticals were worth $45,000 at the end of the most recent quarter. Institutional investors own 86.18% of the company's stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright upgraded shares of Milestone Pharmaceuticals to a "buy" rating and set a $5.00 price objective for the company in a research note on Thursday, June 5th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $7.00.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.